Background Venlafaxine extendedVenlafaxine extendedrelease (ER) has proven efficacy in the release (ER) has proven efficacy in the treatment of anxiety symptoms in major treatment of anxiety symptoms in major depression, generalised anxiety disorder depression, generalised anxiety disorder and social anxiety disorder. and social anxiety disorder.
Venlafaxine extended-release (ER) is a Venlafaxine extended-release (ER) is a serotonin-noradrenaline reuptake inhibitor serotonin-noradrenaline reuptake inhibitor with little or no affinity for muscarinic, with little or no affinity for muscarinic, histaminergic or adrenergic receptors histaminergic or adrenergic receptors (Muth (Muth et al et al, 1986) . Its efficacy, safety and , 1986) . Its efficacy, safety and tolerability in treating depression (Smith tolerability in treating depression (Smith et al et al, 2002) , generalised anxiety disorder , 2002), generalised anxiety disorder (Gelenberg (Gelenberg et al et al, 2000) and social anxiety , 2000) and social anxiety disorder (Allgulander disorder (Allgulander et al et al, 2004) (IR) have suggested that it is effective in the treatment of panic disit is effective in the treatment of panic disorder (Pollack order (Pollack et al et al, 1996) . This random-, 1996) . This randomised, double-blind, placebo-controlled trial ised, double-blind, placebo-controlled trial further examines the safety and efficacy of further examines the safety and efficacy of venlafaxine ER in out-patients with panic venlafaxine ER in out-patients with panic disorder. disorder.
METHOD METHOD

Study design Study design
This was a randomised, double-blind, This was a randomised, double-blind, parallel-group study conducted at 50 sites parallel-group study conducted at 50 sites in Canada, Europe and South Africa in Canada, Europe and South Africa comparing flexible-dose treatment with comparing flexible-dose treatment with venlafaxine ER and placebo in adult outvenlafaxine ER and placebo in adult outpatients who met the criteria for panic patients who met the criteria for panic disorder with or without agoraphobia disorder with or without agoraphobia according to the according to the Diagnostic and Statistical Diagnostic and Statistical Manual of Mental Disorders Manual of Mental Disorders (4th edn, (4th edn, DSM-IV; American Psychiatric Associa-DSM-IV; American Psychiatric Association, 1994) . The institutional review board tion, 1994). The institutional review board for each site and the regulatory agencies for for each site and the regulatory agencies for each country approved the protocol and each country approved the protocol and written informed consent was received written informed consent was received from all participants before randomisation. from all participants before randomisation.
Sample selection Sample selection
Eligible out-patients were men and women Eligible out-patients were men and women at least 18 years of age who met DSM-IV at least 18 years of age who met DSM-IV criteria for panic disorder for at least 6 criteria for panic disorder for at least 6 months before study day 1. Confirmation months before study day 1. Confirmation of the primary diagnosis of panic disorder of the primary diagnosis of panic disorder and exclusion of other psychiatric diagand exclusion of other psychiatric diagnoses such as major depressive disorder noses such as major depressive disorder and generalised anxiety disorder was made and generalised anxiety disorder was made using the DSM-IV and the modified Miniusing the DSM-IV and the modified MiniInternational Neuropsychiatric Interview International Neuropsychiatric Interview (Sheehan (Sheehan et al et al, 1998) . Participants were , 1998). Participants were required to have a Clinical Global required to have a Clinical Global Impression -Severity (CGI-S) (Guy, 1976) Impression -Severity (CGI-S) (Guy, 1976 ) score score 5 54, a minimum of four or more 4, a minimum of four or more full-symptom panic attacks during the full-symptom panic attacks during the 4 weeks before the screening visit, and at 4 weeks before the screening visit, and at least two full-symptom panic attacks least two full-symptom panic attacks during the 14 during the 14+ +3-day placebo lead-in 3-day placebo lead-in period between the screening visit and baseperiod between the screening visit and baseline (study day line (study day 7 71) to be eligible for the 1) to be eligible for the study. For the Panic and Anticipatory study. For the Panic and Anticipatory Anxiety Scale (PAAS; Sheehan, 1983), Anxiety Scale (PAAS; Sheehan, 1983) , participants were given diary cards to participants were given diary cards to record daily details regarding their panic record daily details regarding their panic attack frequency (including symptoms, attack frequency (including symptoms, situational or unexpected) and anticipatory situational or unexpected) and anticipatory anxiety, and the investigator then comanxiety, and the investigator then completed the scale after interview to verify pleted the scale after interview to verify the information in the diary. the information in the diary.
Individuals were excluded if they met Individuals were excluded if they met diagnostic criteria for any clinically importdiagnostic criteria for any clinically important Axis I or Axis II disorder, current or ant Axis I or Axis II disorder, current or predominant, within 6 months of study predominant, within 6 months of study day 1, or if they had a history of alcohol day 1, or if they had a history of alcohol dependence or misuse (as defined in dependence or misuse (as defined in DSM-IV) within 1 year of study day 1. DSM-IV) within 1 year of study day 1. (Lipman, 1982) 2, a Covi Anxiety Scale (Lipman, 1982) total score less than or equal to their Raskin total score less than or equal to their Raskin Depression Scale (Lipman, 1982) total Depression Scale (Lipman, 1982) total score, or a Raskin Depression Scale total score, or a Raskin Depression Scale total score score 4 49 or single-item score 9 or single-item score 4 43 at 3 at screening were also excluded. screening were also excluded.
Individuals were excluded if they had Individuals were excluded if they had received treatment with venlafaxine IR or received treatment with venlafaxine IR or ER within 6 months of study day 1, if they ER within 6 months of study day 1, if they had taken investigational drugs, antihad taken investigational drugs, antipsychotics or fluoxetine, or had regularly psychotics or fluoxetine, or had regularly used benzodiazepines or triptans within used benzodiazepines or triptans within 30 days of study day 1; had taken other 30 days of study day 1; had taken other antidepressants, monoamine oxidase inhiantidepressants, monoamine oxidase inhibitors, non-benzodiazepine anxiolytics, or bitors, non-benzodiazepine anxiolytics, or other psychopharmacological drugs (inother psychopharmacological drugs (including lithium, stimulants, or sedativecluding lithium, stimulants, or sedativehypnotics or herbal products intended to hypnotics or herbal products intended to treat anxiety or depression) within 14 days treat anxiety or depression) within 14 days of study day 1; had undergone investigaof study day 1; had undergone investigational procedures within 30 days of study tional procedures within 30 days of study day 1 or electroconvulsive therapy within day 1 or electroconvulsive therapy within 60 days; had taken non-psychopharmaco-60 days; had taken non-psychopharmacological drugs with psychotropic effects logical drugs with psychotropic effects unless they had been maintained at a stable unless they had been maintained at a stable dose for at least 3 months before study day dose for at least 3 months before study day 1 and the patient was expected to continue 1 and the patient was expected to continue taking the drug without dose changes taking the drug without dose changes 3 5 2 3 5 2
B R I T I S H J O UR N A L O F P SYC HI AT RY B R I T I S H J O UR N A L O F P S YC H I AT RY
Venlafaxine extended-release capsules Venlafaxine extended-release capsules in panic disorder in panic disorder
Flexible-dose, double-blind, placebo-controlled study Flexible-dose, double-blind, placebo-controlled study throughout the study; or had initiated or throughout the study; or had initiated or changed the intensity of formal psychochanged the intensity of formal psychotherapy or cognitive-behavioural therapy therapy or cognitive-behavioural therapy within 30 days of study day 1. within 30 days of study day 1. Other reasons for exclusion were the Other reasons for exclusion were the presence of clinically significant abnormal presence of clinically significant abnormal findings on laboratory tests, electrocardiofindings on laboratory tests, electrocardiogram (ECG), vital signs or physical examingram (ECG), vital signs or physical examination; a history or presence of clinically ation; a history or presence of clinically important medical conditions; and, in important medical conditions; and, in women of childbearing potential, pregwomen of childbearing potential, pregnancy, lactation or not using a medically nancy, lactation or not using a medically acceptable form of contraception. A positive acceptable form of contraception. A positive test result for any drug of misuse at the test result for any drug of misuse at the screening visit required either immediate screening visit required either immediate exclusion or discussion with the medical exclusion or discussion with the medical monitor as to whether a negative result of monitor as to whether a negative result of a retest was acceptable for inclusion in the a retest was acceptable for inclusion in the study. All concomitant treatments prohibstudy. All concomitant treatments prohibited before study day 1 were also prohibited ited before study day 1 were also prohibited during the study. during the study.
Drug administration Drug administration
After a 14 After a 14+ +3-day single-blind, placebo 3-day single-blind, placebo lead-in period, participants were lead-in period, participants were randomly assigned to receive double-blind randomly assigned to receive double-blind venlafaxine venlafaxine ER or placebo for up to 10 ER or placebo for up to 10 weeks, followed by a taper period of up weeks, followed by a taper period of up to 14 days (which could be omitted or to 14 days (which could be omitted or prolonged if clinically indicated). Participrolonged if clinically indicated). Participants returned for a post-study evaluation pants returned for a post-study evaluation 4-10 days after taking the last dose of study 4-10 days after taking the last dose of study medication. A 37.5 mg dose was used for medication. A 37.5 mg dose was used for the first 4 days of treatment and then the first 4 days of treatment and then increased to 75 mg. If clinically indicated, increased to 75 mg. If clinically indicated, the dose could be increased to 150 mg the dose could be increased to 150 mg venlafaxine ER (or two placebo capsules) venlafaxine ER (or two placebo capsules) after day 14 and to a maximum of after day 14 and to a maximum of 225 mg venlafaxine ER (or three placebo 225 mg venlafaxine ER (or three placebo capsules) after day 21. Dosage decreases capsules) after day 21. Dosage decreases were permitted at any time during the study were permitted at any time during the study to improve to improve tolerance at the discretion of the tolerance at the discretion of the investigator, but after study day 7, the investigator, but after study day 7, the minimum daily dose allowed was one capminimum daily dose allowed was one capsule in the morning (75 mg venlafaxine ER sule in the morning (75 mg venlafaxine ER or placebo). Those unable to tolerate or placebo). Those unable to tolerate 75 mg venlafaxine ER were withdrawn 75 mg venlafaxine ER were withdrawn from the study. from the study.
Efficacy assessments Efficacy assessments
The primary efficacy assessment, the PAAS, The primary efficacy assessment, the PAAS, was administered at the screening visit and was administered at the screening visit and on study days on study days 7 71, 7, 14, 21, 28, 42, 56 and 1, 7, 14, 21, 28, 42, 56 and 70 , along with the CGI-S and the Phobia 70, along with the CGI-S and the Phobia Scale (Sheehan, 1983) . The Clinical Global Scale (Sheehan, 1983) . The Clinical Global Impression -Improvement (CGI-I; Guy, Impression -Improvement (CGI-I; Guy, 1976) scale was assessed starting on study 1976) scale was assessed starting on study day 7 and at each time point thereafter. day 7 and at each time point thereafter. The final on-therapy evaluation for each The final on-therapy evaluation for each measure was performed within 3 days of measure was performed within 3 days of the last full dose of study medication the last full dose of study medication (before taper). (before taper).
The primary outcome measure was the The primary outcome measure was the percentage of participants who were free percentage of participants who were free from full-symptom panic attacks ( from full-symptom panic attacks (5 54 4 symptoms) at the on-therapy evaluation. symptoms) at the on-therapy evaluation. The post-baseline full-symptom panic The post-baseline full-symptom panic attack frequency from the PAAS was evaluattack frequency from the PAAS was evaluated in 2-week (14-day) periods, and for the ated in 2-week (14-day) periods, and for the PAAS, the on-therapy evaluation included PAAS, the on-therapy evaluation included the last 14 days of data collected during the last 14 days of data collected during the on-therapy period. the on-therapy period.
Secondary outcome measures comSecondary outcome measures comprised the change from baseline in fullprised the change from baseline in fullsymptom panic attack frequency (based symptom panic attack frequency (based on the PAAS), response and remission. on the PAAS), response and remission. Response to treatment was defined as a Response to treatment was defined as a CGI-I score of 1 (very much improved) or CGI-I score of 1 (very much improved) or 2 (much improved). Remission was defined 2 (much improved). Remission was defined using the CGI-I and CGI-S. Patients were using the CGI-I and CGI-S. Patients were considered to be in remission at a given considered to be in remission at a given evalua evaluation using the CGI-I if they had tion using the CGI-I if they had zero zero full-symptom panic attacks on the full-symptom panic attacks on the PAAS and a CGI-I score of 1 (very much PAAS and a CGI-I score of 1 (very much improved) at any 2-week evaluation and improved) at any 2-week evaluation and 3 5 3 3 5 3 however, did not change the results obtained using the modified ITT population of 328 reported here. Of note, however, did not change the results obtained using the modified ITT population of 328 reported here.Of note, 49 participants had major protocol violations identified by the sponsor before unmasking. Efficacy analyses 49 participants had major protocol violations identified by the sponsor before unmasking. Efficacy analyses performed on the per-protocol population, excluding those with protocol violations that might affect the study performed on the per-protocol population, excluding those with protocol violations that might affect the study results, did not differ significantly from the analyses for the modified ITT population.Therefore, only the results results, did not differ significantly from the analyses for the modified ITT population.Therefore, only the results of the efficacy analyses with the modified ITT population described above are reported. Completers were of the efficacy analyses with the modified ITT population described above are reported. Completers were defined as those in the ITT population whose last Panic and Anticipatory Anxiety Scale evaluation was at least defined as those in the ITT population whose last Panic and Anticipatory Anxiety Scale evaluation was at least 9 weeks after the first. 9 weeks after the first.
at the on-therapy evaluation. Using the at the on-therapy evaluation. Using the CGI-S, patients were considered to be in re-CGI-S, patients were considered to be in remission at a given evaluation if they had mission at a given evaluation if they had zero full-symptom panic attacks on the zero full-symptom panic attacks on the PAAS and a CGI-S score of 1 or 2 PAAS and a CGI-S score of 1 or 2 (1 (1¼normal, not at all ill; 2 normal, not at all ill; 2¼borderline borderline mentally ill) at any 2-week evaluation and mentally ill) at any 2-week evaluation and at the on-therapy evaluation. Other secondat the on-therapy evaluation. Other secondary efficacy measures analysed at each 2-ary efficacy measures analysed at each 2-week time point or at the time of discontiweek time point or at the time of discontinuation included anticipatory anxiety and nuation included anticipatory anxiety and limited-symptom panic attacks (both limited-symptom panic attacks (both measures from the PAAS), the CGI-S and measures from the PAAS), the CGI-S and CGI-I, the Phobia Scale fear and avoidance CGI-I, the Phobia Scale fear and avoidance factors, and the Covi Anxiety Scale. factors, and the Covi Anxiety Scale.
At baseline and on study day 70, particiAt baseline and on study day 70, participants were evaluated on the Quality of Life pants were evaluated on the Quality of Life Enjoyment and Satisfaction Questionnaire Enjoyment and Satisfaction Questionnaire (Q-LES-Q; Endicott (Q-LES-Q; Endicott et al et al, 1993) , the , 1993), the Sheehan Disability Scale (Sheehan, 1983) Sheehan Disability Scale (Sheehan, 1983) and an exploratory resource utilisation in and an exploratory resource utilisation in panic disorder (RUPD) assessment comprispanic disorder (RUPD) assessment comprising a series of single-item responses measuring a series of single-item responses measuring unscheduled use of various healthcare ing unscheduled use of various healthcare services. services.
Safety and tolerability assessments Safety and tolerability assessments
All 'treatment-emergent' adverse events All 'treatment-emergent' adverse events were reported, including those not conwere reported, including those not considered to be drug related and those that sidered to be drug related and those that occurred during the taper/post-study occurred during the taper/post-study period. Safety assessments were based on period. Safety assessments were based on reports of adverse events and results of reports of adverse events and results of routine physical examinations, measureroutine physical examinations, measurements of vital signs, laboratory determinaments of vital signs, laboratory determinations, and ECG. Vital signs (supine and tions, and ECG. Vital signs (supine and standing blood pressure and supine pulse) standing blood pressure and supine pulse) were evaluated at screening and baseline, were evaluated at screening and baseline, at each visit during the double-blind period, at each visit during the double-blind period, and at the post-study visit. Weight was and at the post-study visit. Weight was evaluated at baseline (study day evaluated at baseline (study day 7 71) and 1) and on study day 70. Electrocardiogram recordon study day 70. Electrocardiogram recordings were obtained at screening and on ings were obtained at screening and on study day 70. Laboratory investigations study day 70. Laboratory investigations were performed at screening and on study were performed at screening and on study day 70, and included haematology, blood day 70, and included haematology, blood chemistry, free thyroxine index (screening chemistry, free thyroxine index (screening visit only), urine drug screen, urinalysis visit only), urine drug screen, urinalysis and a serum beta-human chorionic gonadoand a serum beta-human chorionic gonadotropin pregnancy test for women of tropin pregnancy test for women of childbearing potential childbearing potential (at the screening (at the screening visit and any time that pregnancy was visit and any time that pregnancy was suspected). suspected).
If a participant left the study before the If a participant left the study before the end of the double-blind period (study day end of the double-blind period (study day 70 70+ +3 days), all of the above assessments 3 days), all of the above assessments were performed on the last day on which were performed on the last day on which the individual took the full dose of study the individual took the full dose of study medication (before taper) or as soon as medication (before taper) or as soon as possible thereafter. The post-study evaluapossible thereafter. The post-study evaluations were performed 4-10 days after the tions were performed 4-10 days after the participant took the last dose of doubleparticipant took the last dose of doubleblind or taper study medication. blind or taper study medication.
Statistical analyses Statistical analyses
Statistical analyses of efficacy measures were Statistical analyses of efficacy measures were performed on the intent-to-treat (ITT) popuperformed on the intent-to-treat (ITT) population using last-observation-carried-forward lation using last-observation-carried-forward ( (LOCF) and final on-therapy values. The LOCF) and final on-therapy values. The ITT population included participants who ITT population included participants who had a baseline PAAS evaluation, took at had a baseline PAAS evaluation, took at least one dose of study medication and least one dose of study medication and had at least 7 days of PAAS data during had at least 7 days of PAAS data during the double-blind period, and had at least the double-blind period, and had at least one on-therapy double-blind evaluation one on-therapy double-blind evaluation for the primary efficacy variable during for the primary efficacy variable during visits on days 7-70 or within 3 days of visits on days 7-70 or within 3 days of stopping the study medication, before stopping the study medication, before taper. The safety population consisted of taper. The safety population consisted of those who completed the pre-study period those who completed the pre-study period and took at least one dose of randomly and took at least one dose of randomly assigned study medication under doubleassigned study medication under doubleblind conditions. blind conditions. The percentage of those free from PAAS The percentage of those free from PAAS full-symptom panic attacks was analysed full-symptom panic attacks was analysed using logistic regression with treatment using logistic regression with treatment group and site as factors (sites with five or group and site as factors (sites with five or fewer patients were combined). The median fewer patients were combined). The median change in panic attack frequency and anchange in panic attack frequency and anticipatory anxiety data from the PAAS were ticipatory anxiety data from the PAAS were analysed with the Mann-Whitney analysed with the Mann-Whitney U U-test -test (Wilcoxon rank sum test). The remission (Wilcoxon rank sum test). The remission and CGI-I responder data were analysed and CGI-I responder data were analysed by the Fisher exact test. The Phobia Scale, by the Fisher exact test. The Phobia Scale, Covi-Raskin, HRSD, CGI-I and CGI-S Covi-Raskin, HRSD, CGI-I and CGI-S data were analysed by analysis of covaridata were analysed by analysis of covariance (ANCOVA) with treatment and site ance (ANCOVA) with treatment and site as the factors and the baseline scores as as the factors and the baseline scores as covariates. covariates.
The sample size computation was based The sample size computation was based on estimates from the literature: the percenon estimates from the literature: the percentage of those free from panic attacks was tage of those free from panic attacks was expected to be roughly 50% in the expected to be roughly 50% in the venlafaxine-treated group compared with venlafaxine-treated group compared with 30% in the placebo-treated group. It was 30% in the placebo-treated group. It was also estimated that 140 ITT participants also estimated that 140 ITT participants per treatment arm would be needed to per treatment arm would be needed to provide a 90% power for a two-sided provide a 90% power for a two-sided test at the 0.05 significance level. To test at the 0.05 significance level. To 3 5 4 3 5 4 Improvement on each domain of the Improvement on each domain of the Sheehan Disability Scale was defined as Sheehan Disability Scale was defined as reduction from baseline and analysed using reduction from baseline and analysed using ANCOVA with treatment as the main ANCOVA with treatment as the main effect and centre and baseline score as coeffect and centre and baseline score as covariates. The Q-LES-Q was evaluated as variates. The Q-LES-Q was evaluated as improvement (increase) from baseline on improvement (increase) from baseline on each domain using ANCOVA with treateach domain using ANCOVA with treatment as the main effect and the baseline ment as the main effect and the baseline score and centre as covariates. The RUPD score and centre as covariates. The RUPD data were analysed using a data were analysed using a w w 2 2 -test with -test with treatment group as the exposure variable treatment group as the exposure variable and any use of a specific type of healthcare and any use of a specific type of healthcare service versus no use of that healthcare service versus no use of that healthcare service as the dichotomous outcome service as the dichotomous outcome variable. variable.
RESULTS RESULTS
Disposition of participants Disposition of participants
Of 531 individuals screened, 361 were ranOf 531 individuals screened, 361 were randomly assigned to the venlafaxine ER or domly assigned to the venlafaxine ER or placebo groups; of these, 355 were included placebo groups; of these, 355 were included in safety analyses and 328 were included in in safety analyses and 328 were included in efficacy analyses (Fig. 1) . A total of 265 efficacy analyses (Fig. 1) . A total of 265 participants completed the 10 weeks of the participants completed the 10 weeks of the double-blind period. Treatment-emergent double-blind period. Treatment-emergent adverse events were the most common reaadverse events were the most common reason for withdrawal in the venlafaxine ER son for withdrawal in the venlafaxine ER group (16 participants, 9%) and lack of group (16 participants, 9%) and lack of efficacy was the most common reason for efficacy was the most common reason for withdrawal in the placebo group (17 partiwithdrawal in the placebo group (17 participants, 10%). There were no significant cipants, 10%). There were no significant differences between treatment groups in differences between treatment groups in primary reasons for withdrawal during the primary reasons for withdrawal during the double-blind period. The mean daily doses double-blind period. The mean daily doses of venlafaxine ER for those in the ITT of venlafaxine ER for those in the ITT population ranged from 114.8 population ranged from 114.8+ +36.9 mg 36.9 mg at week 3 to 162.9 at week 3 to 162.9+ +60.6 mg at week 10, 60.6 mg at week 10, and no individual received a mean daily and no individual received a mean daily dose greater than 200 mg. dose greater than 200 mg.
Participant characteristics Participant characteristics and baseline severity and baseline severity
Most baseline and demographic characterMost baseline and demographic characteristics were similar between the venlafaxine istics were similar between the venlafaxine ER and placebo groups (Table 1) , although ER and placebo groups (Table 1) , although there was a higher mean frequency of there was a higher mean frequency of full-symptom panic attacks at baseline for full-symptom panic attacks at baseline for the venlafaxine ER group compared with the venlafaxine ER group compared with the placebo group (12.5 the placebo group (12.5 v v. 9.5, . 9.5, respectively; respectively; P P¼0.078). 0.078).
Efficacy Efficacy
At the final on-therapy evaluation, the At the final on-therapy evaluation, the primary end point, 55.0% of venlafaxine primary end point, 55.0% of venlafaxine ER-and 52.4% of placebo-treated partici-ER-and 52.4% of placebo-treated participants were free from full-symptom panic pants were free from full-symptom panic attacks, a statistically non-significant differattacks, a statistically non-significant difference (Fig. 2) . The median reduction from ence (Fig. 2) . The median reduction from baseline in full-symptom panic frequency baseline in full-symptom panic frequency was significantly greater for the venlafaxine was significantly greater for the venlafaxine ER group (Fig. 3) . A significantly higher ER group (Fig. 3) . A significantly higher proportion of the venlafaxine ER group proportion of the venlafaxine ER group responded to treatment (CGI-I score of 1 responded to treatment (CGI-I score of 1 or 2), beginning at week 3 (Fig. 4) and or 2), beginning at week 3 (Fig. 4) and experienced CGI-I remission, beginning at experienced CGI-I remission, beginning at week 6 (Fig. 5) . Improvement in fear and week 6 (Fig. 5) . Improvement in fear and avoidance factors of the Phobia Scale was avoidance factors of the Phobia Scale was significantly greater for the venlafaxine significantly greater for the venlafaxine ER group than for the placebo group, ER group than for the placebo group, beginning at week 6 and continuing beginning at week 6 and continuing through the remainder of the study, with through the remainder of the study, with the exception of week 8 for the avoidance the exception of week 8 for the avoidance factor (Fig. 6 ). Venlafaxine ER was assofactor (Fig. 6 ). Venlafaxine ER was associated with significantly greater improveciated with significantly greater improvement than placebo in observed scores for ment than placebo in observed scores for the 'work' and 'social life/leisure activities' the 'work' and 'social life/leisure activities' domains of the Sheehan Disability Scale, domains of the Sheehan Disability Scale, but not 'family life and home responsibut not 'family life and home responsibilities' (Fig. 7) . A significantly greater bilities' (Fig. 7) . A significantly greater proportion of venlafaxine ER-treated partiproportion of venlafaxine ER-treated participants were free from limited-symptom cipants were free from limited-symptom panic attacks at the final on-therapy evaluapanic attacks at the final on-therapy evaluation compared with those who received plation compared with those who received placebo, and the venlafaxine ER group showed cebo, and the venlafaxine ER group showed 3 5 5 3 5 5 measured by the Panic and Anticipatory Anxiety Scale (PAAS) (during each preceding 2-week period). measured by the Panic and Anticipatory Anxiety Scale (PAAS) (during each preceding 2-week period).
Wilcoxon rank sum test on change from baseline for PAAS full-symptom panic attacks. Wilcoxon rank sum test on change from baseline for PAAS full-symptom panic attacks. P P obtained from obtained from Z Z approximation to Wilcoxon statistics on difference from baseline; * approximation to Wilcoxon statistics on difference from baseline; *P P5 50.05 venlafaxine ER 0.05 venlafaxine ER v. v. placebo; FOT, placebo; FOT, final on-therapy evaluation; -final on-therapy evaluation; -----^---, placebo ( ---, placebo (n n¼168); ---168); ---& &---, venlafaxine ER ( ---, venlafaxine ER (n n¼160). 160). significantly greater improvement in significantly greater improvement in adjusted mean CGI-S scores, CGI-I total adjusted mean CGI-S scores, CGI-I total scores and Covi Anxiety Scale scores, scores and Covi Anxiety Scale scores, median time spent experiencing anticimedian time spent experiencing anticipatory anxiety, and Q-LES-Q 'overall life patory anxiety, and Q-LES-Q 'overall life satisfaction' (Table 2) . satisfaction' (Table 2 ). Significant differences in favour of Significant differences in favour of venlafaxine on the Q-LES-Q were also venlafaxine on the Q-LES-Q were also demonstrated in 'subjective feelings of demonstrated in 'subjective feelings of well-being' (0.63 well-being ' (0.63 v. v v. 0.31; 0.31; P P¼0.026). 0.026). No significant differences were observed beNo significant differences were observed between the venlafaxine ER group and the platween the venlafaxine ER group and the placebo group for the remaining three domains cebo group for the remaining three domains ('household duties', 'school/coursework' ('household duties', 'school/coursework' and 'leisure time activities'). No significant and 'leisure time activities'). No significant between-group differences in healthcare between-group differences in healthcare utilisation were observed. utilisation were observed.
Safety and tolerability Safety and tolerability
Overall, treatment-emergent adverse events Overall, treatment-emergent adverse events were reported by 138 (78%) of the placebowere reported by 138 (78%) of the placebotreated group and 152 (86%) of the venlatreated group and 152 (86%) of the venlafaxine ER-treated group (Table 3) . Eleven faxine ER-treated group (Table 3) . Eleven individuals had events that precipitated individuals had events that precipitated withdrawal from the trial: 5 in the placebo withdrawal from the trial: 5 in the placebo group (1 each with unintended pregnancy, group (1 each with unintended pregnancy, infection, vascular purpura, myocardial ininfection, vascular purpura, myocardial infarction and anxiety) and 6 in the venlafaxfarction and anxiety) and 6 in the venlafaxine ER group (1 each with accidental ine ER group (1 each with accidental overdose, unintended pregnancy, deep overdose, unintended pregnancy, deep thrombophlebitis, colitis, panic attack and thrombophlebitis, colitis, panic attack and metrorrhagia). The treatment-emergent metrorrhagia). The treatment-emergent adverse events that most frequently caused adverse events that most frequently caused discontinuation of treatment in the venladiscontinuation of treatment in the venlafaxine ER group (reported by faxine ER group (reported by 5 52%) were 2%) were anorexia, nausea, insomnia and sweating. anorexia, nausea, insomnia and sweating.
Venlafaxine ER treatment was assoVenlafaxine ER treatment was associated with few clinically important ciated with few clinically important changes in laboratory tests, vital sign results changes in laboratory tests, vital sign results or ECG assessments. Mean changes in or ECG assessments. Mean changes in laboratory values at final on-therapy evalaboratory values at final on-therapy evaluation included significant increases from luation included significant increases from baseline in total cholesterol (0.18 mmol/l, baseline in total cholesterol (0.18 mmol/l, P P5 50.01) and low-density lipoprotein 0.01) and low-density lipoprotein (LDL) cholesterol (0.12 mmol/l, (LDL) cholesterol (0.12 mmol/l, P P5 50.05) 0.05) in the venlafaxine ER group, and nonin the venlafaxine ER group, and nonsignificant decreases in the placebo group significant decreases in the placebo group ( (7 70.05 mmol/l and 0.05 mmol/l and 7 70.07 mmol/l, respec-0.07 mmol/l, respectively). Between-group comparisons were tively). Between-group comparisons were significant for both variables (total significant for both variables (total cholesterol, cholesterol, P P¼0.032; LDL, 0.032; LDL, P P¼0.017). 0.017).
Two participants, both in the venlafaxTwo participants, both in the venlafaxine ER group, experienced clinically ine ER group, experienced clinically important changes in vital signs (one important changes in vital signs (one with tachycardia and one with increased with tachycardia and one with increased blood pressure). The venlafaxine ER and blood pressure). The venlafaxine ER and placebo groups differed significantly in placebo groups differed significantly in mean changes from baseline in supine mean changes from baseline in supine pulse rate (2.18 beats/min pulse rate (2.18 beats/min v. v. 0.12 beats/ 0.12 beats/ min, respectively; min, respectively; P P¼0.007) and weight 0.007) and weight ( (7 70.72 kg 0.72 kg v. v. 0.21 kg, respectively; 0.21 kg, respectively; P P¼0.002). 0.002).
Individual clinically important ECG Individual clinically important ECG results were observed for four participants, results were observed for four participants, all in the placebo group. No participant all in the placebo group. No participant had a QTc interval greater than 500 ms. had a QTc interval greater than 500 ms. Mean changes from baseline in ECG variMean changes from baseline in ECG variables at the final on-therapy evaluation ables at the final on-therapy evaluation included, for the venlafaxine ER group, included, for the venlafaxine ER group, a decrease in PR interval ( a decrease in PR interval (7 74.58 ms, 4.58 ms, P P4 40.01) and increases in QTc interval 0.01) and increases in QTc interval (4.02 ms, (4.02 ms, P P¼NS) and ECG-measured heart NS) and ECG-measured heart rate (3.38 beats/min, rate (3.38 beats/min, P P5 50.001), and for 0.001), and for 3 5 6 3 5 6
Fig. 5 Fig. 5 Remission rates (Clinical Global Impression^Improvement Remission rates (Clinical Global Impression^Improvement¼1 and panic free; intent-to-treat 1 and panic free; intent-to-treat population, last-observation-carried-forward analysis); full-symptom panic attacks measured by the Panic and population, last-observation-carried-forward analysis); full-symptom panic attacks measured by the Panic and Anticipatory Anxiety Scale. Anticipatory Anxiety Scale. P P obtained from Fisher's exact test; * obtained from Fisher's exact test; *P P5 50.05, ** 0.05, **P P5 50.01 venlafaxine ER 0.01 venlafaxine ER v. v. placebo; placebo;
FOT, final on-therapy evaluation; FOT, final on-therapy evaluation; , placebo ( , placebo (n n¼168); 168); , venlafaxine ER ( , venlafaxine ER (n n¼160). 160). Response rates (Clinical Global Impression^Improvement¼1 or 2; intent-to-treat population, last1or 2; intent-to-treat population, lastobservation-carried-forward analysis). observation-carried-forward analysis). P P obtained from Fisher's exact test; * obtained from Fisher's exact test; *P P5 50.05, ** 0.05, **P P5 50.01 venlafaxine ER 0.01 venlafaxine ER v. v. placebo; FOT, final on-therapy evaluation; placebo; FOT, final on-therapy evaluation; , placebo ( , placebo (n n¼168); 168); , venlafaxine ER ( , venlafaxine ER (n n¼160). 160).
the placebo group, a non-significant the placebo group, a non-significant increase in PR interval (1.72 ms) and increase in PR interval (1.72 ms) and non-significant decreases in QTc interval non-significant decreases in QTc interval ( (7 74.32 ms) and ECG-measured heart rate 4.32 ms) and ECG-measured heart rate ( (7 71.45 beats/min). Between-group com-1.45 beats/min). Between-group comparisons were significant for all three variparisons were significant for all three variables (PR interval, ables (PR interval, P P¼0.01; QTc interval, 0.01; QTc interval, P P¼0.035; ECG-measured heart rate, 0.035; ECG-measured heart rate, P P5 50.001). None of the participants had 0.001). None of the participants had any clinically important findings on physiany clinically important findings on physical examination, and no other statistically cal examination, and no other statistically significant changes from baseline or differsignificant changes from baseline or differences between groups were deemed cliniences between groups were deemed clinically important by the medical monitor. cally important by the medical monitor.
DISCUSSION DISCUSSION
The results of this study demonstrate that The results of this study demonstrate that venlafaxine ER is safe, well-tolerated and venlafaxine ER is safe, well-tolerated and efficacious in the short-term treatment of efficacious in the short-term treatment of panic disorder. Baseline characteristics of panic disorder. Baseline characteristics of the study population were consistent with the study population were consistent with the typical profile for panic disorder. the typical profile for panic disorder. Although the difference between groups in Although the difference between groups in the percentage of those who achieved the percentage of those who achieved panic-free status, the primary outcome panic-free status, the primary outcome measure, was not statistically significant, measure, was not statistically significant, venlafaxine ER-treated participants had a venlafaxine ER-treated participants had a significantly greater reduction in the significantly greater reduction in the median number of full-symptom panic median number of full-symptom panic attacks compared with placebo at end attacks compared with placebo at end point. The venlafaxine ER-treated group point. The venlafaxine ER-treated group also had significantly greater improvement also had significantly greater improvement compared with placebo in most other compared with placebo in most other secondary outcome measures. secondary outcome measures.
Methodological issues Methodological issues
Assessment of panic attack frequency, and Assessment of panic attack frequency, and in particular panic-free status, in clinical in particular panic-free status, in clinical trials is difficult and correlates poorly with trials is difficult and correlates poorly with global measures of efficacy (Bandelow global measures of efficacy (Bandelow et al et al, , 1995) , as was the case here in the medi-1995), as was the case here in the medication group (55% panic-free cation group (55% panic-free v.
v. 68% re-68% responders). Panic attacks are known to be sponders). Panic attacks are known to be sporadic and highly variable in frequency sporadic and highly variable in frequency and it is not uncommon for there to be a and it is not uncommon for there to be a period of several weeks when no panic period of several weeks when no panic attacks occur (Shear attacks occur (Shear et al et al, 1998) . In fact, , 1998). In fact, up to 50% of those receiving placebo in up to 50% of those receiving placebo in short-term clinical studies are 'panic-free' short-term clinical studies are 'panic-free' at end point (den Boer, 1998) , which is at end point (den Boer, 1998), which is similar to the proportion in this study (i.e. similar to the proportion in this study (i.e. 52%). A meta-analysis by Otto 52%). A meta-analysis by Otto et al et al (2001) found that more recently reported (2001) found that more recently reported trials of selective serotonin reuptake inhibitrials of selective serotonin reuptake inhibitors in panic disorder that included larger tors in panic disorder that included larger sample sizes were associated with smaller sample sizes were associated with smaller panic frequency effect sizes compared with panic frequency effect sizes compared with earlier trials with small sample sizes. If both earlier trials with small sample sizes. If both published and unpublished studies were published and unpublished studies were available, it is likely that even higher available, it is likely that even higher panic-free rates for placebo-treated individpanic-free rates for placebo-treated individuals would be observed (Otto uals would be observed (Otto et al et al, 2001) . , 2001). Thus, failure to detect differences between Thus, failure to detect differences between active treatment and placebo groups in active treatment and placebo groups in panic-free status is not uncommon, even panic-free status is not uncommon, even with agents that are known to be highly with agents that are known to be highly effective in the treatment of panic effective in the treatment of panic disorder. disorder.
Multidimensional assessment Multidimensional assessment
Multidimensional assessment of therapeutic Multidimensional assessment of therapeutic interventions for panic disorder is therefore interventions for panic disorder is therefore considered appropriate (Ballenger considered appropriate (Ballenger et al et al, , 1998). In addition to panic attack fre-1998). In addition to panic attack frequency, four key domains have been identiquency, four key domains have been identified as relevant for the assessment and fied as relevant for the assessment and treatment of panic disorder: anticipatory treatment of panic disorder: anticipatory anxiety; panic-related phobias; well-being anxiety; panic-related phobias; well-being and overall severity of illness; and effect and overall severity of illness; and effect on work, social life, the family and quality on work, social life, the family and quality of life of life (Ballenger (Ballenger et al et al, 1998 ). Global , 1998 . Global measures by clinicians are also clinically measures by clinicians are also clinically important in assessing how the individual important in assessing how the individual has responded to treatment over time has responded to treatment over time (Pollack (Pollack et al et al, 2002) . Our study showed , 2002). Our study showed that the venlafaxine ER group had signifithat the venlafaxine ER group had significant response (CGI-I of 1, very much cant response (CGI-I of 1, very much improved, or 2, much improved) and reimproved, or 2, much improved) and remission (panic-free and CGI-I of 1) rates mission (panic-free and CGI-I of 1) rates based on global measures of improvement based on global measures of improvement compared with placebo, and significantly compared with placebo, and significantly greater improvement in global severity greater improvement in global severity and in symptoms of anticipatory anxiety and in symptoms of anticipatory anxiety and fear/avoidance. Finally, improvement and fear/avoidance. Finally, improvement in a majority of domains representing in a majority of domains representing quality of life and functionality was quality of life and functionality was observed. observed.
Tolerability and safety Tolerability and safety
The increases in total plasma cholesterol The increases in total plasma cholesterol and LDL levels observed in the venlafaxine and LDL levels observed in the venlafaxine ER group relative to the placebo group in ER group relative to the placebo group in this report are consistent with studies of this report are consistent with studies of healthy volunteers that show an increase healthy volunteers that show an increase in LDL after treatment with the selective in LDL after treatment with the selective serotonin reuptake inhibitor paroxetine serotonin reuptake inhibitor paroxetine (Lara (Lara et al et al, 2003) and an increase in total , 2003) and an increase in total plasma cholesterol with mirtazapine, an plasma cholesterol with mirtazapine, an agent that has both serotonergic and agent that has both serotonergic and noradrenergic properties (Lara noradrenergic properties (Lara et al et al, 2003; , 2003; Nicholas Nicholas et al et al, 2003) . Other studies have , 2003). Other studies have reported increased total plasma cholesterol reported increased total plasma cholesterol levels in individuals with anxiety disorders levels in individuals with anxiety disorders (Peter (Peter et al et al, 2002) . The metabolic basis of , 2002). The metabolic basis of such results and their clinical significance such results and their clinical significance merits further investigation. Heart rate merits further investigation. Heart rate and QT interval variability in those with and QT interval variability in those with panic disorder relative to controls has been panic disorder relative to controls has been attributed to abnormal attributed to abnormal a a 2 2 -adrenergic func--adrenergic function (Yeragani tion (Yeragani et al et al, 2003) . Further investi-, 2003) . Further investigation of the differences in heart rate and gation of the differences in heart rate and QTc interval changes from baseline beQTc interval changes from baseline between treatment and placebo groups, as in tween treatment and placebo groups, as in the present study, is desirable. the present study, is desirable.
Summary Summary
Venlafaxine ER was generally safe and well Venlafaxine ER was generally safe and well tolerated in this study. The type and fretolerated in this study. The type and frequency of adverse events and discontinuaquency of adverse events and discontinuation rate attributable to adverse events in tion rate attributable to adverse events in the venlafaxine ER group was similar to the venlafaxine ER group was similar to that seen in individuals with depression, that seen in individuals with depression, generalised anxiety disorder and social generalised anxiety disorder and social anxiety disorder, indicating no additional anxiety disorder, indicating no additional risk of adverse events in those with panic risk of adverse events in those with panic disorder. Together with its superior efficacy disorder. Together with its superior efficacy relative to placebo across most outcome relative to placebo across most outcome measures, the favourable safety and tolermeasures, the favourable safety and tolerability profile of venlafaxine ER suggests ability profile of venlafaxine ER suggests that it is a viable treatment option for panic that it is a viable treatment option for panic disorder. disorder.
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Efficacy of venlafaxine ER in patients with social anxiety Efficacy of venlafaxine ER in patients with social anxiety 3 5 8 3 5 8 Phobia Scale, adjusted mean change from baseline Phobia Scale, adjusted mean change from baseline Venlafaxine ER is safe and well tolerated.
& & The effective dose for venlafaxine ER in the treatment of panic disorder appears to The effective dose for venlafaxine ER in the treatment of panic disorder appears to be comparable to that used in the treatment of depression. be comparable to that used in the treatment of depression.
LIMITATIONS LIMITATIONS
& & Venlafaxine ER was not associated with a significantly greater proportion of Venlafaxine ER was not associated with a significantly greater proportion of individuals who were free from full-symptom panic attacks at the final on-therapy individuals who were free from full-symptom panic attacks at the final on-therapy evaluation. evaluation.
& & Those with comorbid depression or other clinically important psychiatric
Those with comorbid depression or other clinically important psychiatric disorders were excluded from the study. disorders were excluded from the study. Lack of an active comparator in this study limits the conclusions that can be drawn regarding the efficacy of venlafaxine ER compared with other antidepressants. regarding the efficacy of venlafaxine ER compared with other antidepressants.
